abs290.txt	purpose		bevacizumab	is	a	vegf-specific	angiogenesis	inhibitor	indicated	as	anadjunct	to	chemotherapy	for	the	treatment	of	multiple	cancers	hypertension	iscommonly	observed	during	and	high-grade	toxicity	can	limittherapy	or	lead	cardiovascular	complications	factors	that	contribute	tointerindividual	variability	in	blood	pressure	rise	treatmentare	not	well	understood	experimental	design	identify	genomic	regionsassociated	with	bevacizumab-induced	risk	sequencing	candidategenes	flanking	regulatory	regions	was	performed	on	61	patients	treated	withbevacizumab	(19	cases	developed	early-onset	grade	3	42	controlshad	no	reported	first	six	cycles	treatment)	snp-basedtests	common	variant	associations	gene-based	tests	rare	variantassociations	were	174	candidate	genes	results	four	variantsin	independent	linkage	disequilibrium	blocks	between	slc29a1	hsp90ab1	wereamong	top	validation	larger	bevacizumab-treated	cohortssupported	association	rs9381299	early	3+	(p	=0	01	2	4)	systolic	>180	mm	hg	=	0	02	1)	rs834576	associated	calgb	40502	03	9)	these	snp	are	enriched	elements	maypotentially	increase	gene	expression	vitro	overexpression	humanendothelial	cells	disrupted	adenosine	signaling	reduced	nitric	oxide	levelsthat	further	lowered	upon	exposure	conclusions	genomicregion	its	role	regulating	adenosinesignaling	key	targets	investigation	into	pathogenesis	ofbevacizumab-induced	clin	cancer	res	24(19)	4734-44	Â©2018	aacr
